Synthetic cannabinoid URB447 reduced brain injury and white matter damage in newborn rats after oxygen deprivation
The CB1 antagonist/CB2 agonist URB447 significantly reduced brain injury and white matter demyelination in neonatal rats when given either before or 3 hours after hypoxia-ischemia.
Quick Facts
What This Study Found
URB447 strongly reduced brain injury when given before hypoxia-ischemia. When given 3 hours after injury (a clinically feasible window), it still reduced neurodegeneration, white matter damage, astrogliosis, and microglial activation. The CB1 antagonist SR141716A had a comparable protective effect, while the CB1 agonist WIN-55,212-2 reduced URB447's benefit.
Key Numbers
URB447 reduced neurodegeneration and white matter damage when given 3 hours post-injury. CB1 agonist WIN-55,212-2 diminished URB447's protective effect, pointing to CB2 activation and CB1 blockade as the mechanism.
How They Did This
Neonatal rat model of hypoxia-ischemia. URB447 (a CB1 antagonist/CB2 agonist) administered either before or 3 hours after injury. Effects compared with CB1 antagonist SR141716A and CB1 agonist WIN-55,212-2. Brain injury, white matter damage, and inflammatory markers assessed histologically.
Why This Research Matters
Perinatal brain injury from oxygen deprivation affects roughly 1-3 per 1,000 live births and has limited treatment options. A 3-hour therapeutic window is clinically relevant for treating affected newborns.
The Bigger Picture
The finding that CB1 blockade combined with CB2 activation provides neuroprotection adds nuance to the role of the endocannabinoid system in brain injury, where different receptor subtypes may play opposing roles.
What This Study Doesn't Tell Us
Animal model; neonatal rat brain development does not perfectly match human timing; single compound studied; long-term functional outcomes not assessed.
Questions This Raises
- ?Would URB447 provide neuroprotection in human neonates?
- ?Could this approach complement existing hypothermia therapy for perinatal brain injury?
Trust & Context
- Key Stat:
- Neuroprotection observed even with a 3-hour treatment delay after brain injury
- Evidence Grade:
- Single animal study in neonatal rats; no long-term functional outcome data.
- Study Age:
- Published in 2020.
- Original Title:
- The Synthetic Cannabinoid URB447 Reduces Brain Injury and the Associated White Matter Demyelination after Hypoxia-Ischemia in Neonatal Rats.
- Published In:
- ACS chemical neuroscience, 11(9), 1291-1299 (2020)
- Authors:
- Carloni, Silvia, Crinelli, Rita, Palma, Linda, Álvarez, Francisco J, Piomelli, Daniele, Duranti, Andrea, Balduini, Walter, Alonso-Alconada, Daniel
- Database ID:
- RTHC-02451
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How is this different from medical cannabis?
URB447 is a synthetic compound that blocks CB1 receptors while activating CB2 receptors. This is a very different profile from THC (which activates CB1) or CBD. The neuroprotective effect appears to come from this specific combination of CB1 blockade and CB2 activation.
Could this be used to treat birth-related brain injuries?
The study provides early evidence of a potential therapeutic approach, but it is an animal study. Significant further research, including safety studies and clinical trials, would be needed before any human application.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-02451APA
Carloni, Silvia; Crinelli, Rita; Palma, Linda; Álvarez, Francisco J; Piomelli, Daniele; Duranti, Andrea; Balduini, Walter; Alonso-Alconada, Daniel. (2020). The Synthetic Cannabinoid URB447 Reduces Brain Injury and the Associated White Matter Demyelination after Hypoxia-Ischemia in Neonatal Rats.. ACS chemical neuroscience, 11(9), 1291-1299. https://doi.org/10.1021/acschemneuro.0c00047
MLA
Carloni, Silvia, et al. "The Synthetic Cannabinoid URB447 Reduces Brain Injury and the Associated White Matter Demyelination after Hypoxia-Ischemia in Neonatal Rats.." ACS chemical neuroscience, 2020. https://doi.org/10.1021/acschemneuro.0c00047
RethinkTHC
RethinkTHC Research Database. "The Synthetic Cannabinoid URB447 Reduces Brain Injury and th..." RTHC-02451. Retrieved from https://rethinkthc.com/research/carloni-2020-the-synthetic-cannabinoid-urb447
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.